A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS.

By L. Mu, S. Feng. Journal of Controlled Release, 2003

739 citations recorded by the source corpus.

Subfields: Biomaterials, Oncology, Pharmaceutical Science

View Paper: https://www.semanticscholar.org/paper/da65a8b162a98530aad687e14364350dae743df4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. F. Danhier
2. V. Préat
3. Olivier Féron
4. L. Brannon-Peppas
5. C. Jérôme
6. J. Blanchette
7. Jun Wu
8. Vladimir Torchilin

In Oncology

1. L. Brannon-Peppas
2. Olivier Féron
3. J. Blanchette
4. V. Préat
5. F. Danhier

In Pharmaceutical Science

1. L. Brannon-Peppas
2. J. Blanchette
3. V. Préat

Citations in the corpus

• Nanoparticle and targeted systems for cancer therapy. (2004, methodology): “Another group has added vitamin E TGPS (d-a-tocopheryl polyethylene glycol 1000 succinate) as an emulsifier and matrix component to PLGA nanoparticles for paclitaxel release [28].”
• Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. (2009, methodology): “Preparation of Paclitaxel-loaded nanoparticles First, nanoparticles were prepared by simple emulsion technique [18].”
• Design of Curcumin Loaded PLGA Nanoparticles Formulation with Enhanced Cellular Uptake, and Increased Bioactivity in vitro and Superior Bioavailability in vivo (2009, neutral): “This approach has been used to deliver natural products such as coenzyme Q10 [28], estradiol [29], and ellagic acid [30] and chemotherapeutic agents such as paclitaxel [31], and doxorubicin [32].”